What Is PNC-27?
PNC-27 is a chimeric peptide designed around two functional domains: a 12-amino-acid leader sequence from the signal peptide of human h-ras (for membrane targeting) fused to amino acids 12–26 of the p53 tumor suppressor protein — the region that interacts with MDM2. In cancer cells, MDM2 is overexpressed on the plasma membrane, where PNC-27 binds and initiates membrane disruption. Normal cells, which do not express membrane-associated MDM2, are not affected.
Mechanism of Selective Cytotoxicity
PNC-27's selectivity for cancer cells stems from differential membrane expression of HDM2 (the human homolog of MDM2). In transformed cells, HDM2 is constitutively expressed on the outer plasma membrane surface. PNC-27 binds this membrane-bound HDM2, inserts into the lipid bilayer, and forms pores — causing rapid cell death via membranolysis. Normal, non-transformed cells lack this membrane HDM2 expression and are therefore resistant.
Cancer Models Studied
PNC-27 has been tested in cell lines and animal models of pancreatic cancer, breast cancer, leukemia, melanoma, and lung adenocarcinoma. Across these models it has consistently shown potent and selective cytotoxic activity against cancer cells with no significant toxicity to normal cells.
Research Status
PNC-27 remains in preclinical research. Its non-receptor mechanism of action — membrane disruption rather than intracellular pathway modulation — distinguishes it from conventional cancer therapeutics and has generated interest as a scaffold for novel anticancer agents.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Sarafraz-Yazdi E, Mumin S, Engel D, et al., 2010, Proceedings of the National Academy of Sciences - The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Sarafraz-Yazdi E, Bowne WB, Engel D, et al., 2010, Cancer Chemotherapy and Pharmacology - PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
Sarafraz-Yazdi E, Fridman D, Lin B, et al., 2022, Biomedicines - Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
Pincus MR, Sarafraz-Yazdi E, et al., 2024, Annals of Clinical & Laboratory Science - PNC-27 Kills Cervical Cancer Cells but Not Untransformed Cervical Cells, an Effect that is Enhanced by Ketone Bodies
Pincus MR, Bowne W, Silberstein M, Sarafraz-Yazdi E, 2025, Medical Research Archives - Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer
Kanovsky M, Raffo A, Drew L, et al., 2015, Annals of Clinical & Laboratory Science - Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Sarafraz-Yazdi E, et al., 2020, Anticancer Research - Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
Rahmani R, Darroudi M, Gharanfoli M, 2022, Iran J Basic Med Sci - The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Sookraj KA, Bowne WB, Adler V, 2010, Cancer Chemother Pharmacol - Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Sarafraz-Yazdi E, Bowne WB, Adler V, 2010, Proc Natl Acad Sci U S A - The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells
Bowne WB, Sookraj KA, Vishnevetsky M, 2008, Ann Surg Oncol - Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
Pincus MR, Silberstein M, Zohar N, 2024, Biomedicines